top of page

Ariad Pharmaceuticals agrees to sell European operations to Incyte

Ariad Pharmaceuticals has agreed to sell its European operations and out-license the commercial rights to Iclusig in Europe to the US-based biopharmaceutical firm Incyte.

Under the deal, Incyte will make a $140m upfront payment to Ariad plus pay royalties of up to 50% on European sales of Iclusig.

Incyte will also take over Ariad's team of 125 employees in Europe.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page